Kornimate/medical-research-clean huggingface dataset:
follow-up of patients with obstructive sleep apnea in primary care.

Conditions: OSA

Summary: the objective of the study is to compare the results of a coordinated and interactive program for the treatment, monitoring and control of patients with a moderate-severe diagnosis of obstructive sleep apnea (osa) and treated with positive continuous pressure (cpap), with the currently established situation. methodology: equivalence randomized comparative study . it will include patients with diagnosis of moderate-severe osa (apnea-hypopnea index \>=15) that should start treatment with (cpap). participating center is hospital santa maría-arnau de vilanova in lleida (spain).these patients will be randomized to two monitoring groups (1: monitoring in the sleep disorders unit, 2: monitoring in primary care consultations) once the osas diagnosis has been made and it was indicated that treatment with cpap. patients will be carried out in both groups the same follow-up visits in two study arms: basal, 1 month, 3 months and 6 months. primary outcomes: number of hours of use per day (according to the accountant of the cpap), so that use \>= 4h/day is defined as good adherence to the treatment. secondary outcomes: daytime sleepiness, patient satisfaction, adverse events related to cpap treatment. it will be collected demographic ,clinics and anthropometric variables. at the end of follow-up primary and secondary outcomes will be compared between two groups.


Eligibility criteria:
inclusion criteria: * men and women over 18 years old. * patients with osa diagnosis performed in the sleep units * written informed consent signed. exclusion criteria: * previous cpap treatment for osa diagnosis * psycho-physical inability to complete questionnaires. * presence of any previously diagnosed sleep disorders: narcolepsy, insomnia, chronic sleep deprivation, regular use of hypnotic or sedative medications and restless leg syndrome * patients with respiratory diseases (overlap syndrome, hypoventilation, restrictive diseases) * a medical history that may interfere with the study objectives or, in the opinion of the investigator, compromise the conclusions. * any medical factor, social or geographical, that may jeopardize patient compliance.(e.g., alcohol consumption (more 80 gr/day in men and more than 60 gr / day in women), no fixed address, disorientation, or a history of non-compliance).

Keywords: osa cpap treatment primary care efficacy
research tissue bank

Conditions: Myelofibrosis; Idiopathic Myelofibrosis; Essential Thrombocythemia; Polycythemia Vera

Summary: this study that will allow for the preservation and/or storage of a small portion one or more of the following tissues: * peripheral blood * bone marrow * bone marrow biopsy * a phlebotomized unit of blood * spleen cells * toenail clippings this material will be used for the study of myeloproliferative disorders (mpd) by researchers. the goals of this research study are to understand the causes of mpds, how to diagnose them more easily and how to treat them better. mpd is a disease affecting hematopoietic stem cells. hematopoietic stem cells are cells that make blood cells. these stem cells grow in the center portion of the bones called bone marrow. under some conditions, these cells are also found in blood. there are several diseases, which are classified as mpd. these include polycythemia vera (too many red blood cells), essential thrombocythemia (too many platelets), and idiopathic myelofibrosis (abnormal blood cells and fibers build up in the bone marrow). these syndromes carry a high risk of developing leukemia. it is important to continue to learn more about these blood cancers and to learn more about the effectiveness and potential side effects of various treatments.


Eligibility criteria:
inclusion criteria: * patients diagnosed with philadelphia chromosome negative myeloproliferative disorders (mpd) polycythemia vera (pv), idiopathic myelofibrosis (im), and essential thrombocythemia (et) are eligible. * newly diagnose mpd patients as well as previously treated for a mpd are eligible. * signed informed consent is required from each patient at the time of enrollment. exclusion criteria: * patients currently participating in experimental treatment arms of mpd-rc protocols, or other experimental treatment protocols are not eligible during the period they are on study.

Keywords: myeloproliferative disease myelofibrosis idiopathic myelofibrosis essential thrombocythemia polycythemia vera
culprit lesion only pci versus multivessel pci in cardiogenic shock

Conditions: Cardiogenic Shock; Acute Myocardial Infarction; Complications

Summary: the study compares the therapies of instant multivessel balloon angioplasty plus stent implantation or the balloon angioplasty plus stent implantation of the infarct artery alone with any possible graduated later treatment of the other vessels in patients with acute myocardial infarction with cardioganic shock. the main study hypothesis is to explore if culprit vessel only pci with potentially subsequent staged revascularization in comparison to immediate multivessel revascularization by pci in patients with cardiogenic shock complicating acute myocardial infarction reduces the incidence of 30- day mortality and/or severe renal failure requiring renal replacement therapy.


Eligibility criteria:
inclusion criteria: cardiogenic shock complicating acute myocardial infarction (stemi or nstemi) with obligatory: i) planned early revascularization by pci ii) multivessel coronary artery disease defined as more than 70% stenosis in at least 2 major vessels (more than 2 mm diameter) with identifiable culprit lesion iii) 1. systolic blood pressure less than 90 mmhg for more than 30 min or 2. catecholamines required to maintain pressure more than 90 mmhg during systole and iv) signs of pulmonary congestion v) signs of impaired organ perfusion with at least one of the following criteria a) altered mental status b) cold, clammy skin and extremities c) oliguria with urine output less than 30 ml/h d) serum-lactate more than 2.0 mmol/l vi) informed consent exclusion criteria: * resuscitation more than 30 minutes * no intrinsic heart action * cerebral deficit with fixed dilated pupils (not drug-induced) * need for primary urgent bypass surgery (to be determined after diagnostic angiography) * single vessel disease * mechanical cause of cardiogenic shock * onset of shock more than 12 h * massive lung emboli * age more than 90 years * shock of other cause (bradycardia, sepsis, hypovolemia, etc.) * other severe concomitant disease with limited life expectancy \<6 months * pregnancy * known severe renal insufficiency (creatinine clearance \<30 ml/kg)

Keywords: cardiogenic shock infarction multivessel coronary artery disease angioplasty
a study of single dose of lp-003 in healthy adult subjects

Conditions: Chronic Spontaneous Urticaria

Summary: the purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of lp-003 in healthy subjects.


Eligibility criteria:
inclusion criteria: 1. healthy males or females aged ≥18 and ≤ 50 years. 2. male subjects must weigh ≥50 kg, and female subjects must weigh ≥45 kg, with a bmi between 19.0 and 28.0 kg/m² (inclusive). 3. male subjects and their partners or female subjects must agree to use one or more non-pharmaceutical contraceptive methods (such as total abstinence, condoms, iuds, partner ligation, etc.) during the trial period and for 6 months after the trial, and do not plan to donate sperm or eggs. 4. the subjects fully understand the purpose, nature, method and possible adverse reactions of the experiment, and voluntarily participate in the experiment and sign the informed consent. 5. the subjects were able to communicate well with the researchers and complete the study according to the protocol. exclusion criteria: 1. people who are allergic to the experimental drug and any of its excipients, have a history of allergy to monoclonal antibodies, and are allergic to multiple drugs and food. 2. patients who have been or are currently suffering from any clinically serious diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatric and metabolic abnormalities, or any other diseases that can interfere with the test results. 3. patients who had undergone surgery within 3 months before the trial that the researchers judged would affect drug absorption, distribution, metabolism, and excretion, or had surgery within 4 weeks prior to the trial, or planned to have surgery during the study period. 4. any history of infection within 14 days prior to administration. 5. a person who is currently infected with parasites or has traveled to an endemic area within the last 3 months or 24 weeks prior to administration. 6. pregnant and lactating women. 7. hepatitis b surface antigen, hepatitis c virus antibodies, human immunodeficiency virus antibodies, treponema pallidum antibodies a positive person. 8. patients who have received any biological agent (including antibodies or derivatives such as omazumab) within 16 weeks prior to administration (or 5 half-lives, selecting the longer time period). 9. participants who had participated in other clinical trials within 3 months prior to screening. 10. the investigator deems any condition unsuitable for study participation.
post-operative mobilization for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: this study will investigate the effect of one week of immobilization following carpal tunnel release surgery versus no immobilization.


Eligibility criteria:
inclusion criteria: * patients undergoing open carpal tunnel release will be included in this study. * patients must have clinical evidence of carpal tunnel syndrome. * patients must have positive emg results. * english speaking patients only. patient selection factors include: * ability and willingness to follow instructions. * patients who are able and willing to return for follow-up evaluations. * patients of all races and genders. * patients who are able to follow care instructions. exclusion criteria: * patients less than 18 years old. * patients who are pregnant. * patients unwilling or unable to comply with a rehabilitation program for carpal tunnel release who indicate difficulty or inability to return for follow-up visits prescribed by the study protocol. * patients who qualify for inclusion in the study, but refuse consent to participate in the study.
efficiency of twice daily formoterol versus once daily tiotropium in patients with gold a/b copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: chronic obstructive pulmonary disease (copd) is a disease state characterized by persistent airflow limitation and associated with an accelerated decline in lung function, impaired quality of life, hospitalization, and increased mortality. as a major public health problem, copd is predicted to rank as the fifth burden of diseases in the world by 2020. thus, prevention of exacerbations is a important goal in the management of copd. the global initiative for chronic obstructive lung disease (gold) scientific committee launched a joint project in 1998. its goals were to raise awareness of copd and to improve prevention and treatment of copd patients around the world. in the 2017 gold guidelines, inhaled long-acting bronchodilators, including inhaled long-acting muscarinic antagonists (lamas) and inhaled long-acting beta-agonists (labas), are recommended for the management of all stable copd patients. however, it is not known whether laba or lama will be more effective for initial relief of symptoms in patients with gold a/b copd. in this multicenter, randomized study, the investigators evaluate the efficacy of formoterol(laba) and tiotropium(lama) in the treatment of patients with gold a/b copd. the primary endpoint is postbronchodilator fev1, and the secondary endpoints include the frequency of copd exacerbation, other lung function parameters, ccq score and mmrc/cat score.


Eligibility criteria:
inclusion criteria: clinical diagnosis of group a or group b stable copd. must be able to inhale formoterol or tiotropium. exclusion criteria: asthma. cystic fibrosis. bronchiectasis. lung cancer. glaucoma. tachyarrhythmia or other serious heart diseases. prostatic hyperplasia.

Keywords: copd gold formoterol tiotropium
evaluation of root coverage after the use of coronally advanced flap either with advanced paltelet rich fibrin or subepithilial connective tissue graft in treatment of miller class i and ii gingival recession.

Conditions: Gingival Recession

Summary: patients with miller class i , ii gingival recession will be divided into 2 groups (control, intervention).the control one will receive coronally advanced flap with subepithililal connective tissue graft harvested from the palate while the intervention one will have coronally advanced flap with advanced platelet rich fibrin(a-prf).as it represent a new generation of platelet concentrate allow for better healing and root coverage results. null hypothesis: in patients with miller class i and ii gingival recession, there is no difference in amount of root coverage (mm) following the application of sctg+a-prf compared to caf+sctg.

* population (p): patients with single miller class i, ii gingival recessions. * intervention (i): coronally advanced flap (caf) plus platelet rich fibrin (a-prf). * comparator (c): coronally advanced flap (caf) plus subepithelial connective tissue graft (sctg). * primary outcome (o): root coverage (mm). * time frame: 9 months. * study design: randomized controlled clinical trial. * patients are to be selected from the outpatient clinic of the department of oral medicine and periodontology-cairo university

Eligibility criteria:
inclusion criteria: * systemically healthy patients 18 years old and older both males and females. * good oral hygiene after phase i therapy. * miller's class i or ii gingival recession. * not using antibiotics, steroids, chemotherapy or other medications that may modify results of the surgery and healing. * cooperative patients able and accept to come for follow up appointments exclusion criteria: * pregnant or lactating females. * current smokers. * patients with any systemic disease that may affect the periodontal healing. * teeth with endodontic treatment, buccal restoration or caries. * patients with poor oral hygiene

Keywords: advanced platelet rich fibrin,a-prf
predictive value of a mrna signature and liquid biopsy in diffuse large b cell lymphoma

Conditions: Diffuse Large B Cell Lymphoma

Summary: the purpose of this study is to determine the predictive value of a mrna signature and liquid biopsy in patients with diffuse large b cell lymphoma.


Eligibility criteria:
inclusion criteria: * biopsy proved diffuse large b cell lymphoma * newly diagnosed between 2000-01 and 2015-12 exclusion criteria: * patients with biopsy samples unavailable
mri screening for brain metastases among patients with triple negative or her2+ stage ii or iii breast cancer

Conditions: Breast Cancer

Summary: the goal of this multi-centre, prospective study is to assess the frequency of asymptomatic brain metastasis in patients with stage ii or iii triple negative or her2 positive breast cancer. the main questions it aims to answer are: 1. what proportion of patients with stage ii or iii triple negative or her2 positive breast cancer have asymptomatic brain metastases identified on a screening contrast-enhanced magnetic resonance imaging (or computed tomography when magnetic resonance is not possible) of the brain? 2. how do patients feel about undergoing brain imaging to screen for asymptomatic brain metastasis? 3. what clinical and tissue-based biomarkers are associated with asymptomatic detection of brain metastasis? participants will undergo a brain imaging, collect one blood sample to perform ctdna analysis, and fill the testing morbidities index (tmi) after imaging is done. procedures must take place within one year of initial diagnosis, either prior to or after completion of (neo)-adjuvant systemic therapy.


Eligibility criteria:
inclusion criteria: 1. age \> 18. 2. triple negative or her2+ breast cancer (as per 2018 asco/cap guidelines). 3. stage ii or iii disease. 4. patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen may participate. 5. ability to understand and the willingness to sign a written informed consent document. exclusion criteria: 1. creatinine clearance \<30 ml/min using the cockcroft-gault equation (in accordance with the product monograph for gadavist iv contrast. 2. pregnant women are not permitted to participate given that the safety of iv contrast is unknown in this population. 3. patients with central nervous system symptoms that are concerning for brain metastases that would otherwise be referred for brain imaging.

Keywords: her2 triple negative brain metastasis
nutritional supplement compliance study

Conditions: Undernutrition

Summary: disease-related malnutrition is common across healthcare settings in the uk and if left untreated, may have severe consequences. one of the strategies commonly used to combat malnutrition is the use of oral nutritional supplements (ons). however, there is uncertainty about the optimal way of delivering ons to patients to maximize compliance and nutrient intake. this randomised study will investigate the effect of different modes of delivery (ad libitum versus instructions on timing/serving volume) of ons used in addition to the diet on total nutrient intake, compliance, nutritional status and outcome in participants at risk of malnutrition. participants will be randomised to receive one of two ons (high energy or standard) for 4 weeks in addition to food, either taken 'ad libitum', or according to instruction on what to take and when. the primary outcome measure is nutrient intake. secondary outcome measures include compliance and acceptability of ons, appetite, anthropometry, muscle strength, quality of life and gastro-intestinal tolerance.


Eligibility criteria:
inclusion criteria: * male or female * age \> 18 years * at risk of malnutrition (medium or high risk of malnutrition with 'malnutrition universal screening tool', 'must' score ≥ 1) * competent to provide written informed consent and able to answer questions * no requirement for tube or parenteral feeding * willingness to take part in the study and to follow the study protocol exclusion criteria: * requirement for tube or parenteral nutrition * participants receiving palliative care * participants with chronic renal disease requiring dialysis * participants with liver failure * participants that are pregnant or lactating * participation in other studies
re-fixating dislocated scleral fixing intra-ocular lens

Conditions: Intraocular Lens Complication

Summary: to minimize multiple manipulations and to decrease the economical burden; here, we describe how to utilize the patient's own dislocated intraocular lens to re-fixate with the sclera.

when a scleral fixated intraocular lens (iol) is displaced; routinely it is extracted and exchanged with another iol and re-fixated to the sclera or another modality can be used. both can carry many complications due to multiple manipulations. nevertheless, suture and/or haptic end exposure is another expected future complication, which can range from foreign body sensation to endophthalmitis. here, the investigators utilized the same participant's iol with minimum manipulations and the haptic ends buried inside scleral pockets to prevent future exposure and complications. the pocket entry is sutured with 8/0 vicryl, which is absorbable, to overcome complications.

Eligibility criteria:
inclusion criteria: * dislocated primary scleral fixed iol exclusion criteria: * iris claw iol * anterior chamber iol

Keywords: intraocular lens dislocation scleral re-fixation scleral fixation
novel staging schemes for siewert type ii esophagogastric junction adenocarcinoma: a real-world data cohort study from seer database

Conditions: Adenocarcinoma of the Esophagogastric Junction

Summary: this study have two aims, the first is to explore the optimal cutoff of tln for siewert type ii aeg using the surveillance, epidemiology, and end results (seer) database the second is to provide a more accurate staging for siewert type ii aeg patients.


Eligibility criteria:
inclusion criteria: siewert type for adenocarcinoma of the esophagogastric junction; pathologically confirmed t1-4an0-3m0 stage after surgery after a pathological examination of the lns.

Keywords: esophagogastric junction total examined lymph nodes staging
prevention of per-partum fetal hypoxia: measure of placental elasticity and viscosity during labor

Conditions: Placental Elastography; Fetal Monitoring

Summary: fetal heart rate (fhr) monitoring during labor aims to detect fetuses at risk of intrapartum hypoxia in order to accelerate their birth before the constitution of sequelae such as anoxic encephalopathy and cerebral palsy. but the positive predictive value of fhr monitoring is low, and many second-line tests have been proposed but none of them has been proven to be conclusive. measure of placental elasticity and viscosity during labor could be a new second line test to complete the fhr monitoring. several studies have shown that placental elasticity is increased in case of gestational diabetes, preeclampsia, or intrauterine growth restriction, but no study has focused on placental elasticity during labor. the investigators hypothesize that placental elasticity and viscosity could reflect the quality of maternal-fetal exchanges during labor, and could help to detect fetus at risk of intrapartum hypoxia. the first aim of this study is to describe the values of placental elasticity and viscosity during different points in the labor: beginning of the labor, beginning of the active phase of the first stage of labor, and passive phase of the second stage of labor. secondary aims of this study are: to describe the values of placental elasticity and viscosity in case of oxytocin infusion, in case of abnormal fhr, and ex-vivo after placental expulsion. this unicentric observational prospective study will include 150 patients with singleton pregnancy, without pathology, with spontaneous labor at term.


Eligibility criteria:
inclusion criteria: * singleton pregnancy * spontaneous labor at term * body mass index \< 30 at the beginning of the pregnancy * anterior, lateral or fundal placenta * epidural analgesia at the beginning of the labor * normal fetal heart rate at the beginning of the labor exclusion criteria: * gestational diabetes * preeclampsia * intrauterine growth restriction
aortic dimensions in turner syndrome

Conditions: Turner Syndrome

Summary: an observational study of 102 women with turner syndrome followed for 6 years with a two-yearly examination including echo, mri of the heart and 24 ambulatory blood pressure. it has been found that besides an significantly increased risk of congenital cardiac malformations, ts have an increased risk of developing cardiac disease including the life threatening condition of aortic dilatation and rupture. the aim of the study is to describe the cardiac conditions of ts, evaluate different methods of examination and identify possible risc factors.


Eligibility criteria:
inclusion criteria: * turner syndrome * age 18-70 years exclusion criteria: * extreme adipositas * contraindications to a mri scan * malignant disease

Keywords: turner syndrome aortic dimensions blood pressure aortic dilatation aortic rupture